Loading clinical trials...
Loading clinical trials...
This phase 1, single-center, open-label study explores the safety of escalating doses of chimeric antigen receptor T cells (CAR-T) cells in subjects with relapsed/refractory triple-negative breast can...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
UNC Lineberger Comprehensive Cancer Center
Collaborators
NCT07471841 · IDH1 Mutation, Relapsed / Refractory AML
NCT06500481 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, and more
NCT07655934 · Breast Cancer
NCT06188520 · ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)
NCT06400563 · Breast Cancer
University of North Carolina
Chapel Hill, North Carolina
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions